Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Follow-Up Questions
Who is the CEO of Medicenna Therapeutics Corp?
Dr. Fahar Merchant is the Chairman of the Board of Medicenna Therapeutics Corp, joining the firm since 2011.
What is the price performance of MDNAF stock?
The current price of MDNAF is $0.7268, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp belongs to Biotechnology industry and the sector is Health Care
What is Medicenna Therapeutics Corp market cap?
Medicenna Therapeutics Corp's current market cap is $60.6M
Is Medicenna Therapeutics Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Medicenna Therapeutics Corp, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
